ClinicalTrials.gg
Active, not recruitingNCT05731752Updated Jul 22, 2024

Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HX009 in Advanced Solid Tumors, sponsored by Hangzhou Hanx Biopharmaceuticals, Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-22.

Sponsored by Hangzhou Hanx Biopharmaceuticals, Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as active, not recruiting.
  • Registered 2 years 8 months after the study started (first participant enrolled May 2020, registered Jan 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open, multiple-dose administration dose exploratory clinical phase I study to evaluate the safety, tolerability, and PK profile of HX009 Injection in patients with advanced solid tumors and to provide a preliminary measure of its antitumor efficacy. It includes Phase Ia and Phase Ib.

phase Ia is a dose exploratory study to evaluate safety, tolerability, and to determine the MTD and/or RP2D.The sponsor and investigator will adjust the magnitude of the dose escalation and the dosing cycle based on the safety and tolerability of HX009 Injection and the PK data that have been obtained, as well as decide whether to add an unplanned dose or dosing cycle to the trial, and recommend the RP2D.The Ia phase dose escalation design model is shown below. The planned dosing cycle for this study is once every 2 weeks (14 days) (Q2W) with IV HX009.

Based on the result of phase 1a,10 mg/kg Q2W was the recommended dose for phase 1b. The aimed population for 1b is patients diagnosed with advanced melanoma, and divided into two cohorts:: cohort A ,untreated patients with unresectable or metastatic advanced melanoma;and Cohort B, patients with unresectable or metastatic malignant melanoma that had been treated with immune checkpoint inhibitor therapy. The enrollment of Cohort B will start first.,and whether the cohort A will be initiated depends on the results of the cohort B .The up to 80 patients will be enrolled in Phase Ib.

Read the detailed description

The study is divided into a screening, treatment, and follow-up period. The Treatment Period may continue to be administered until the investigator determines that the subject no longer benefits, or the subject develops intolerable toxicity, or the subject withdraws informed consent, or the disease progresses or is treated with an antineoplastic agent other than those specified in the protocol, or the subject dies, or is lost to follow-up, or a Phase Ib subject has been administered for 2 years (whichever occurs earliest).

Subjects who withdraw from the study/terminate treatment for any reason are required to return for 1 follow-up visit after the last dose, to collect as many RO blood samples as possible after discontinuation (only partial subjects in Phase Ib), and to collect clinical data on safety as well as survival. During the subsequent follow-up period (for Phase Ib only), subjects or family members will receive a telephone visit to inquire about survival and antitumor therapy.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Hangzhou Hanx Biopharmaceuticals, Ltd. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In Phase Ia.

Subjects must meet all of the following enrollment criteria to be enrolled in this study:

  1. Voluntarily sign an form, understand the study and be willing to follow and be capable of completing all trial procedures;
  2. Male or female, age 18-70 years (including borderline values);
  3. score: 0 to 1;
  4. Advanced malignant solid tumors diagnosed by cytology or histopathology and after failure of standard treatment (disease progression or intolerable) or in the absence of effective therapies;
  5. Subjects must have at least one extracranial lesion for efficacy assessment according to the Solid Tumor Evaluation Criteria ( 1.1), including both measurable and non-. The number of subject cases with all non-measurable lesions must not exceed 1/3 of the total enrollment;
  6. Expected survival ≥ 12 weeks;
  7. If prior antitumor therapy has been received, the following are required:

    • ≥ 3 weeks between systemic radiation therapy and the first dose, and ≥ 2 weeks between localized radiation therapy or radiation therapy for bone ;
    • Prior chemotherapy, immunotherapy ( antibody, PD-L1 antibody, or CTLA-4 antibody, etc.), biologic therapy (tumor vaccine, cytokine, or growth factor for cancer control), and targeted therapy ≥ 4 weeks from the first administration interval (small molecule targeted agent therapy ≥ 2 weeks from the first administration interval);
    • Prior immunotherapy with PD-1 antibody, PD-L1 antibody, or CTLA-4 antibody without permanent discontinuation due to prior immunotherapy;
    • Prior treatment with a significant anti-tumor herbal or proprietary Chinese medicine ≥ 2 weeks from the first dose;
  8. In the case of patients with asymptomatic Central Nervous System (CNS) metastases or treated asymptomatic , be free of disease progression by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI), be stable for at least 4 weeks, and not require medication;
  9. Have appropriate organ and hematopoietic function and no severe cardiac, pulmonary, hepatic, or renal dysfunction or immunodeficiency based on the following laboratory tests

in phase Ib

Subjects must meet all of the following enrollment criteria to be enrolled in this trial:

  1. Voluntarily sign an informed consent form, understand the study and be willing to follow and be capable of completing all trial procedures;
  2. Male or female, age 18-75 years (including borderline values);
  3. ECOG score: 0 to 1;
  4. Unresectable/metastatic advanced melanoma diagnosed by cytology or histopathology;
  5. Cohort A: No prior systemic therapy for advanced melanoma (prior and adjuvant therapy with last dose completed before 6 months can be enrolled). Cohort A: No prior systemic therapy for advanced melanoma (previous neoadjuvant and adjuvant therapy, completed before 6 months of last dose) Cohort B: Disease progression after treatment with immune checkpoint inhibitors ;
  6. Subjects must have at least one measurable lesion according to the Solid Tumor Evaluation Criteria (RECIST 1.1);
  7. Expected survival ≥ 12 weeks;
  8. have adequate organ and hematopoietic function, and have laboratory results that meet the requirements

Exclusion criteria

Exclusion Criteria:

in Phase Ia:

  • Subjects with any of the following are not eligible for enrollment in this study:

    1. Those who have developed another within 5 years prior to enrollment, with the exception of cured carcinoma in situ of the cervix and cured basal cell carcinoma of the skin;
    2. Failure to recover from adverse effects of prior therapy to a 5.0 grade score of ≤ grade 1, except for residual alopecia areata effects;
    3. Subjects with active, or history of, disease with potential for relapse (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulonephritis, etc.), or at high risk (e.g., have received an organ transplant requiring therapy). However, subjects with the following diseases are allowed to enroll:
  • Type 1 diabetes mellitus that has stabilized with the use of fixed-dose insulin;
  • Autoimmune hypothyroidism requiring only hormone replacement therapy;
  • Skin disorders that do not require systemic therapy (e.g., eczema, rashes covering less than 10% of the body surface, psoriasis without ophthalmologic symptoms, etc.); 4) Anticipated major surgery during this study including the 28-day screening period; 5) Subjects requiring treatment with systemic (dose equivalent to >10 mg prednisone/day) or other immunosuppressive medications within 14 days prior to the first dose or during the study period; enrollment is permitted in the following cases:
  • Subjects are permitted to use topical topical or inhaled glucocorticoids;
  • Short-term (≤ 7 days) use of glucocorticoids for prophylaxis or treatment of non-autoimmune allergic diseases is permitted; 6) Currently suffering from sudden lung disease, interstitial lung disease, interstitial pneumonia, pulmonary fibrosis, acute lung disease, radiation pneumonitis; 7) systemic diseases that have not been controlled and stabilized by treatment, such as cardiovascular diseases (unstable angina pectoris or myocardial infarction before 6 months, etc.) diabetes mellitus, hypertension, etc; 8) arterial or venous thrombosis or embolic events such as cerebrovascular accidents (including ), deep vein thrombosis or pulmonary embolism within 6 months prior to the first dose; 9) History of infection with , or other acquired, congenital immunodeficiency disease, or history of organ transplantation, or stem cell transplantation; 10) a history of tuberculosis, or a history of tuberculosis disease at the time of screening 11) those with active chronic or active Hepatitis B virus carriers, hepatitis B stabilized by drug therapy (DNA titer must not be higher than 500 IU/mL or copy number \<1000copies/ml) and patients with cured hepatitis C (negative HCV RNA test) may be enrolled; 12) Those who have had a serious infection within 4 weeks prior to the first dose or who have had an active infection requiring oral or intravenous antibiotic therapy within the previous 2 weeks;

In phase Ib :

Phase Ib Exclusion Criteria

Subjects with any of the following are not eligible for enrollment in this study:

  1. Histologic or pathologic diagnosis of choroidal malignant melanoma;
  2. Patients with , except those who have been treated and are symptomatically stable. Require ongoing corticosteroids as treatment for CNS disorders, allowing stable doses of anticonvulsant therapy.
  3. Malignancies other than malignant melanoma that have occurred within 5 years prior to enrollment, with the exception of malignancies with negligible risk of or death and/or curative treatment (e.g., adequately treated carcinoma in situ of the cervix, basal or squamous cell skin carcinoma, limited prostate cancer, ductal carcinoma in situ, or stage I uterine cancer);
  4. Uncontrolled pleural effusion, abdominal effusion, or pericardial effusion requiring repeated drainage. Those with indwelling drainage tubes are allowed to be enrolled;
  5. History of blood transfusion within the last 3 months;
  6. hemolytic anemia, autoimmune thrombocytopenia, or Evan syndrome within the last 3 months;
  7. prior bone marrow transplantation or solid organ transplantation;
  8. Failure to recover from adverse effects of prior therapy to a CTCAE 5.0 grade score of ≤ grade 1, excluding alopecia areata;
  9. Major surgery within 4 weeks prior to the first dose of study drug or expected to undergo major surgery during the study period;
  10. Patients who have received prior 7 or SIRpa-targeted therapy;
  11. have received any live or attenuated vaccine within 28 days prior to the first dose of study drug;
  12. have received oral or intravenous antibiotics (including antifungals) 2 weeks prior to the first dose of study drug, except for those who require prophylactic anti-infective therapy (to prevent urinary tract infections or exacerbations of );
  13. Subjects requiring treatment with systemic corticosteroids (dose equivalent to >10 mg prednisone/day) or other immunosuppressive medications within 14 days prior to the first dose of study drug or during the study period; enrollment is permitted under the following conditions:

    • Use of topical topical or inhaled glucocorticoids;
    • Short-term (≤ 7 days) use of glucocorticoids for prophylaxis or treatment of non-autoimmune allergic diseases;
    • Corticosteroids for the replacement therapy of adrenal insufficiency;
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    HX009

    Study treatment: HX009 administered every 2 weeks (14 \[±3\] days) via intravenous infusion.

    Drug: HX009

Interventions

  • DrugHX009

    The subjects will receive HX009 treatment via IV infusion once every 2 weeks at different dose escalation cohorts

    Also known as: Recombinant humanized anti-CD47/PD-1 bifunctional antibody

06

What researchers measure

Primary outcomes

  1. In phase Ia: Incidence of Dose Limiting Toxicities (DLT) of HX009 in patients with advanced solid tumors

    Adverse events (AEs) determined by the investigator are recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0).

    Time frame: At the end of Cycle 2 (each cycle is 14 days)

  2. Incidence of adverse events (AE) of HX009 in patients with advanced solid tumors

    Adverse events (AEs) determined by the investigator are recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0).

    Time frame: Collected adverse events from signing of informed consent through at least 28 days after the end of treatment, or until other cancer treatment regimens have been started (whichever occurs earlier).

  3. In phase IB:Incidence of Dose Limiting Toxicities (DLT) in HX009 in patients with advanced solid tumors

    Incidence and severity of adverse events as assessed by the investigator according to RECIST 1.1;

    Time frame: At the end of Cycle 2 (each cycle is 14 days)

Secondary outcomes

  1. In Phase Ia: Pharmacokinetics (PK): Maximum plasma concentration of drug (Cmax)

    Highest concentration of drug measured in the PK samples

    Time frame: At Cycle 1 ,Cycle 6 and Cycles 2 -5 (each cycle is 14 days)

  2. Pharmacokinetics (PK): Time to reach Cmax (Tmax)

    Time from dosing until collection of the PK samples with the highest drug concentration.

    Time frame: At Cycle 1 ,Cycle 6 and Cycles 2 -5(each cycle is 14 days)

  3. Terminal Half-life (t½)of HX009

    Terminal phase elimination half-life

    Time frame: At Cycle 1 ,Cycle 6 and Cycles 2 -5 (each cycle is 14 days)

  4. Area Under the Serum Concentration-time Curve (AUC)

    The area under the serum concentration-time curve .

    Time frame: At Cycle 1 ,Cycle 6 and Cycles 2 -5 (each cycle is 14 days)

  5. Number of Participants With Positive Anti-Drug Antibody (ADA) of HX009

    ADA blood samples were assayed for anti-HX009 antibodies.

    Time frame: At Cycles 1-6, 9, 13, 17, and then every 8 cycles up to approximately 1 years: within 1 hour before infusion (each cycle is 14 days).

  6. Objective response rate (ORR) of HX009 in patients with solid tumors

    The ORR is defined as the percentage of participants in the analysis population who had a confirmed Complete Response or Partial Response.

    Time frame: Approximately 1 years

  7. Duration of response (DoR) of HX009 in patients with solid tumors

    The DoR is defined as the time from the first recorded response (CR or PR) to the first recorded tumor progression or death due to any cause.

    Time frame: Approximately 1 years

  8. Progression-free survival (PFS) of patients with solid tumors treated with HX009

    The PFS is defined as the time from the start of the first dose to the first documented disease progression or death of any cause.

    Time frame: Approximately 1 years

  9. In Phase Ib: ORR

    objective response rate assessed by the investigator according to RECIST1.1/iRECIST;

    Time frame: Approximately 2 years

  10. In Phase Ib: DCR

    disease control rate assessed by the investigator according to RECIST1.1/iRECIST;

    Time frame: Approximately 2 years

  11. In Phase Ib: PFS

    progress-freee survival assessed by the investigator according to RECIST1.1/iRECIST;

    Time frame: Approximately 2 years

  12. In Phase Ib: Cmax

    Highest concentration of drug measured in the PK samples

    Time frame: Approximately 1 years

  13. In phase Ib:AUC

    Area Under the Serum Concentration-time Curve (AUC)

    Time frame: Approximately 1 years

07

Study locations

1 site
  • Cancer Hospital Chinese Academy of Medical Sciense
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2020 (actual). Primary completion is estimated for Dec 2024, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2023
First posted
Feb 16, 2023
StartActual
May 28, 2020
Primary completionEst.
Dec 30, 2024
CompletionEst.
Dec 30, 2024
Last update
Jul 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05731752
Lead sponsor
Hangzhou Hanx Biopharmaceuticals, Ltd.
Responsible party
Sponsor
First posted
Feb 16, 2023
Start date
May 28, 2020
Primary completion
Dec 30, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Jul 22, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/CD47 Fusion Protein HX009

Start the discussion